Evidence map›Paper›PMID 40736678›Full record

ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

An overview of switching biological therapies for chronic rhinosinusitis with nasal polyposis (CRSwNP).

Talal Alharbi, Nawaf Alsubaie, Ahmad Alroqi

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Switching to dupilumab from other biologic therapies in chronic rhinosinusitis with nasal polyps (CRSWNP): a comparison with biologic-naïve patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Artificial Intelligence in Rhinology: A State-of-the-Art Review of Clinical Readiness and Implementation Pathways.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Talal AlharbiDepartment of Otolaryngology-Head and Neck Surgery, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Nawaf AlsubaieDepartment of Otorhinolaryngology Head & Neck Surgery, King Abdulaziz University Hospital, Riyadh, Saudi Arabia.
Ahmad AlroqiDepartment of Otolaryngology-Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Dr.ahmadalroqi@gmail.com.ORCID http://orcid.org/0000-0002-5275-0255

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2 inflammatory disease, which can lead to significant impact on quality of life due to symptoms of local and systemic inflammation and has a high recurrence rate despite optimal medical or surgical treatment. Recalcitrant CRSwNP can be treated with biological therapies with specific immunological targets, such as IgE (Omalizumab), IL4α receptors (Dupilumab), or IL-5 (Mepolizumab), which have been approved for this use. The purpose of this narrative review was to review the currently available literature on biological therapies for CRSwNP and their switching in cases of inadequate disease control.

methodsKeywords such as 'biologic'; 'anti-IgE'; 'anti-IL5'; 'anti-IL4'; 'sinusitis'; 'chronic rhinosinusitis'; 'nasal polyps'; 'switch'; and 'recurrence' were combined using the 'AND' or 'OR' Boolean operators to search databases including Google Scholar, Medline, and EMBASE; free-text search was also utilized for this purpose.

resultsWhile there is sufficient evidence to support the use of biological therapies for recurrent and refractory CRSwNP despite the use of nasal corticosteroids as an add-on or adjunctive therapy, there is paucity of evidence regarding switching from one biologic to another. Evidence on biologic switching for recurrent CRSwNP supported the use of Dupilumab while switching from anti-IgE or anti-IL5 biologics, due to better symptom control and improved quality of life outcomes.

conclusionBiological treatments for CRSwNP have good real-life efficacy in managing nasal symptoms and improving quality of life. Multidisciplinary consensus from immunologists or allergists, otorhinolaryngologists, and pulmonologists is essential for aiding decision-making regarding switching biologics.

Indexed as

Biological TherapyNasal PolypsRhinitisSinusitisAntibodies, Monoclonal, HumanizedChronic DiseaseHumansInterleukin-5OmalizumabQuality of LifeRhinosinusitisAntibodies, Monoclonal, HumanizeddupilumabInterleukin-5mepolizumabOmalizumabBiologicsChronic rhinosinusitis with nasal polypsDrug efficacyDrug switchingReal-life studies

Identifiers

PMID40736678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.